JSC “Grindeks” informs that the company successfully continues registration of Mildronate® in the People’s Republic of China.

Last week in China, Beijing “Grindeks” management representatives - Chairman of the Council Kirovs Lipmans, R&D Director Nilss Poritis and Head of Regulatory Affairs Department Linda Litina met with the management of China’s State Food and Drug Agency, as well as medication registration and research specialists. The visit was also attended by Latvia’s Ambassador to the People's Republic of China Ingrida Levrence and other representatives of the embassy.

During the meeting, the registration process of Mildronate® was discussed, paying particular attention to the report on pharmacokinetics of the clinical trial of Mildronate®.

Chairman of the Council of JSC “Grindeks” Kirovs Lipmans: “Mildronate® is the original product of “Grindeks”, with which we are purposefully going to enter the highly promising Chinese market. During the meeting, Chinese State Food and Drug Agency's management confirmed that “Grindeks” has fulfilled all the preconditions to open Mildronate® clinical trial. It is planned that in the near future “Grindeks” will start cooperation with several clinical research centers in China.”

Mildronate® is the main original product of “Grindeks”, and its main sales markets are Russia and other CIS countries. In 2010 an international clinical trial on the influence of the original product Mildronate® on the treatment of angina was successfully finished. “Grindeks” altogether invested 1.6 million lats in this research.

To reduce the dominance of one product “Grindeks” has significantly increased turnover amount of other medications and active pharmaceutical ingredients in the product portfolio over the past years. Mildronate® proportion has fallen from 73% to 51%.

On “Grindeks”

“Grindeks” is the leading pharmaceutical company in the Baltic States. Its main fields of action are: research, development, manufacturing and sale of original products, generics and active pharmaceutical ingredients. Product portfolio of “Grindeks” consists of original products, generics and active pharmaceutical ingredients. “Grindeks” specializes in the heart and cardiovascular, CNS and anti-cancer medication therapeutic groups.

Group of “Grindeks” consists of four subsidiary companies in Latvia, Estonia and Russia, as well representative offices in ten countries. Products of the company are exported to more than 40 countries and its export comprises more than 96% of the total turnover. The main markets are: Russia and other CIS countries, the Baltic States, Germany and the Netherlands. JSC “Grindeks” shares are listed in the Official List of “NASDAQ OMX Riga”.

Further information:

Laila Kļaviņa
Head of the Communications Department, JSC “Grindeks”
Phones: (+371) 67083370, (+371) 29256012
Fax: (+371) 67083505
www.grindeks.lv